August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
April 2023 in “Journal of Dermatological Treatment” Tofacitinib helped regrow hair in a teen with a unique pattern of alopecia areata.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
3 citations
,
August 2019 in “Journal of Cancer Research and Therapeutics” Cetuximab can cause unusual hair growth and hair loss.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
November 2025 in “JAAD Case Reports” Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.
19 citations
,
September 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
April 2023 in “Journal of Investigative Dermatology” Aminoacridine and Abemaciclib, especially combined with Minoxidil, show promise for treating hair loss.
19 citations
,
January 2012 in “Dermatology” Topical human epidermal growth factor may effectively treat acne caused by cancer medication.
41 citations
,
December 2019 in “Science Translational Medicine” Anti-EGFR therapy can cause skin issues, but FGF7 treatment might help.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
105 citations
,
October 2018 in “Nature” A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
March 2026 in “Journal of the American Academy of Dermatology” 9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
14 citations
,
December 2013 in “Molecules” Two compounds from Asiasarum heterotropoides roots show potential as lung cancer treatments without harming normal cells.
January 2026 in “Biochemical Pharmacology” 3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.